Table 2 Detailed information and treatment courses for each patient
From: The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
Patient no. | Location of primary lesion | Previous systemic treatment | Locations of lesions for evaluation | Duration of using current treatment (m) | The reason for treatment cease | Best overall response | Status for last follow up | Overall survival (m) |
|---|---|---|---|---|---|---|---|---|
1 | Left forearm | None | Primary lesion and lymphatic metastasis | 6.5 | Patient’s intention | SD | AWD | 83.7 |
2 | Left thigh | AI chemo, Anlotinib | Relapsed thigh lesion, vein tumor thrombosis, Subcutaneous metastasis | 2.9 | Adverse events | PR | AWD | 86.3 |
3 | Right humerus | None | Multiple bone metastasis and tiny pulmonary metastasis | 3.6 | Adverse events | SD | AWD | 9.5 |
4 | Right finger | AI chemo, albumin paclitaxel | Primary relapsed lesion and lymphatic metastasis to axillary fossa | 7.2 | No stopping treatment | PR | AWD | 14.7 |
5 | Right inguinal fold | AI chemo, apatinib, anlotinib, cabozantinib, pazopanib, lenvatinib | Multiple bone metastasis and retroperitoneal lymph node metastasis | 8.3 | Adverse events (tumor rupture in her retroperitoneum) | PR | AWD | 69.4 |
6 | Left upper arm | AI chemo, apatinib | Primary lesion and lymphatic metastasis | 8.0 | Definitive surgery (amputation) | SD | NED | 23.8 |
7 | Left inguinal fold | AI chemo+anlotinib | Primary relapsed lesion locally involving pelvis and lymphatic metastasis | 3.0 | Adverse events (diarrhea) | SD | DOD | 17.2 |
8 | Left upper arm | AI chemo, anlotinib | Primary lesion and lymphatic metastasis, multiple pulmonary metastasis | 10.0 | COVID-19 | SD | AWD | 22.8 |